Data as of Nov 17, 2026 close · Statements through the quarter ended Jun 2026 · Source: Financial Modeling Prep (methodology)
Regencell Bioscience Holdings Limited most recently reported annual revenue of $0, a net loss of $12.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Regencell Bioscience Holdings Limited: net profit was positive in 0 of 8 reported years; the most recent year shows a net loss of $12.0M.
Income Statement — 8 Years (USD millions)
Metric
2019
2020
2021
2022
2023
2024
2025
2026
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Operating Expenses
$0
$1.0M
$1.0M
$8.0M
$6.0M
$5.0M
$4.0M
$12.0M
Operating Profit
$0
−$1.0M
−$1.0M
−$8.0M
−$6.0M
−$5.0M
−$4.0M
−$12.0M
Other Income
$0
$0
$0
$0
$0
$0
$0
$0
Interest
$0
$0
$0
$0
$0
$0
$0
$0
Depreciation
$0
$0
$0
$1.0M
$1.0M
$1.0M
$0
$0
Profit Before Tax
$0
−$1.0M
−$1.0M
−$8.0M
−$6.0M
−$4.0M
−$4.0M
−$12.0M
Tax rate (%)
0.1%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Net Profit
$0
−$1.0M
−$1.0M
−$7.0M
−$6.0M
−$4.0M
−$4.0M
−$12.0M
EPS
$0.00
$0.00
$0.00
−$0.01
−$0.01
−$0.01
−$0.01
−$0.02
Quarterly Results — Last 12 Quarters (USD millions)
2 duplicate period labels in the source data were collapsed.
Metric
Dec '20
Jun '21
Dec '21
Jun '22
Dec '22
Jun '23
Dec '23
Jun '24
Dec '24
Jun '25
Dec '25
Jun '26
Revenue
$0
$0
$0
−$2.3B
$0
$0
$0
$0
$0
$0
$0
$0
Operating Expenses
$0
$0
$4.0M
−$2.3B
$3.0M
$3.0M
$0
$0
$2.0M
$2.0M
$5.0M
$6.0M
Operating Profit
$0
$0
−$4.0M
−$4.0M
−$3.0M
−$3.0M
$0
$0
−$2.0M
−$2.0M
−$5.0M
−$6.0M
Operating Margin
—
—
—
0.2%
—
—
—
—
—
—
—
—
Interest
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Profit Before Tax
$0
−$1.0M
−$4.0M
−$4.0M
−$3.0M
−$3.0M
$0
$0
−$2.0M
−$2.0M
−$5.0M
−$6.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
5.5%
0.0%
0.0%
0.0%
0.0%
0.0%
Net Profit
$0
$0
−$4.0M
−$4.0M
−$3.0M
−$3.0M
$0
$0
−$2.0M
−$2.0M
−$5.0M
−$6.0M
EPS
$0.00
$0.00
−$0.01
−$0.01
−$0.01
−$0.01
$0.00
$0.00
$0.00
$0.00
−$0.01
−$0.01
Over the 8 years reported for Regencell Bioscience Holdings Limited, borrowings decreased from $2.0M in 2019 to $0 in 2026, cash stood at $14.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 14.00 times.
Balance Sheet — 8 Years (USD millions)
Metric
2019
2020
2021
2022
2023
2024
2025
2026
Total Assets
$0
$1.0M
$0
$18.0M
$13.0M
$8.0M
$6.0M
$15.0M
Current Assets
$0
$0
$0
$16.0M
$12.0M
$8.0M
$5.0M
$14.0M
Cash
$0
$0
$0
$6.0M
$2.0M
$3.0M
$2.0M
$14.0M
Inventory
$0
$0
$0
$0
$0
$0
$0
$0
Receivables
$0
$0
$0
$0
$0
$0
$0
$0
Fixed Assets
$0
$0
$0
$1.0M
$1.0M
$0
$1.0M
$0
Capital Work in Progress
$0
$0
$0
$0
$0
$0
$0
$0
Investments
$0
$0
$0
$10.0M
$10.0M
$5.0M
$2.0M
$0
Other Assets
$0
$0
$0
$0
$0
$0
$0
$0
Total Liabilities
$2.0M
$3.0M
$4.0M
$1.0M
$1.0M
$0
$1.0M
$1.0M
Current Liabilities
$2.0M
$3.0M
$4.0M
$1.0M
$1.0M
$0
$1.0M
$1.0M
Borrowings
$2.0M
$3.0M
$4.0M
$1.0M
$0
$0
$1.0M
$0
Other Liabilities
$0
$0
$1.0M
$0
$0
$0
$0
$1.0M
Equity
$0
$0
$0
$0
$0
$0
$0
$0
Reserves
−$2.0M
−$3.0M
−$4.0M
$17.0M
$12.0M
$8.0M
$5.0M
$13.0M
For Regencell Bioscience Holdings Limited, operating cash flow was positive in 0 of 8 reported years; free cash flow in the latest year was negative at $8.0M; free cash flow was positive in 0 of 8 years; financing activities used $2.0M in the latest year, which covers debt repayment, dividends and buybacks.
What is Regencell Bioscience Holdings Limited's annual revenue?
Regencell Bioscience Holdings Limited (RGC) reported annual revenue of $0 in its most recent fiscal year.
What is Regencell Bioscience Holdings Limited's net profit?
Regencell Bioscience Holdings Limited (RGC) reported a net loss of $12.0M in its most recent fiscal year.
What is RGC EV/EBITDA?
Regencell Bioscience Holdings Limited's enterprise value to EBITDA (EV/EBITDA) ratio is -287.68. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.
Revenue and earnings of other Drug Manufacturers - Specialty & Generic stocks